PRFX | PainReform
Quick infosTrade prices
Next ER: November 15, 2021Company ProfilePainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Our proprietary extended release drug-delivery system has the potential to prolong the in vivo activity of APIs (active pharmaceutical ingredients), thus increasing the therapeutic window for patient treatment. Our strategy is to incorporate generic drugs with our proprietary extended release drug-delivery system in order to create extended release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the U.S. Food and Drug Administration (?FDA?). Earnings History
Historical Data
This company doesn't provide a dividend. Talk about PainReform below in comments section below.Do you think you'll buy? Do you already have active trades now? EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. Other ER on Nov 15, 2021 (Same day)            | NotesJump to (Finance sites)         ResearchInvestor pagewww.painreform.comIf you are looking for News & events, Press Release, they are available on their Investors Relationssite. Support this projectIf you want to help pay for server cost or for improving this tool. You can send it via Paypal. Social MediaRecommended Books Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||